Current clinical data show that NGF in bone neoplasms treatment mainly focuses on the treatment of neurogenic tumours and peripheral nerve injury, but its mechanism of action and potential application in bone tumours should not be ignored. This evidence concerns the gene NGF and bone neoplasm.